Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Radiation 'Priming' could make lung cancer treatment more effective

NCT ID NCT07523464

Disease control Sponsor: Anhui Provincial Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests whether giving a small, focused dose of radiation to the center of a lung tumor can safely 'prime' the immune system before standard chemoradiation and immunotherapy. About 24 adults with stage III non-small cell lung cancer that cannot be removed by surgery will take part. The main goal is to check for serious side effects and see if this approach can be smoothly added to usual care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 24 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 to 75 years; * Histologically or cytologically confirmed NSCLC; * Unresectable stage III disease according to the AJCC 8th edition; * Negative for driver gene alterations; * Considered suitable for definitive cCRT by MDT discussion or investigator judgment; * ECOG performance status 0-1; * Presence of a clearly delineable pulmonary primary lesion allowing centrally confined priming treatment planning; * Adequate major organ function as required by the study; * Willingness to participate and provision of written informed consent. Exclusion Criteria: * Presence of distant metastasis; * Positive driver gene alterations; * Prior definitive thoracic radiotherapy or prior systemic antitumor treatment for the current disease; * Active autoimmune disease or need for long-term systemic immunosuppressive therapy; * Active interstitial lung disease, prior severe radiation pneumonitis, or immune-related pneumonitis; * Special primary tumor location such that safety constraints for centrally confined priming radiotherapy cannot be met; * Primary lesion immediately adjacent to the main bronchus, carina, major vessels, or esophagus, such that the investigator judges the lead-in intervention to be excessively risky; * Pregnancy or lactation; * Any other condition that, in the opinion of the investigator, makes the patient unsuitable for this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Locally-advanced non-small cell lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Locally-advanced non-small cell lung cancer Radiotherapy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.